Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Surge Protector: Novel approach to suppressing therapy-induced tumour growth

In a recent groundbreaking study, a team of researchers led by BIDMC’s Dipak Panigrahy, MD, a scientist at the Cancer Center at BIDMC, demonstrated that dead and dying cancer cells killed by conventional cancer treatments paradoxically trigger the inflammation that promotes tumour growth and metastasis.

Now, in a follow-up study published in January in Proceedings of the National Academy of Science (PNAS), Panigrahy and colleagues illuminate the mechanism by which debris generated by ovarian tumour cells targeted by first-line chemotherapy accelerates tumour progression.

Additionally, the researchers describe a novel approach to suppressing the chemotherapy-induced tumour growth.

“Conventional cancer therapy is a double-edged sword – the very treatment meant to control cancer is also helping it to survive and grow,” said Panigrahy, Assistant Professor of Pathology in the Department of Pathology and a Scientist at the Cancer Center at BIDMC

"To prevent tumour recurrence after therapy, it will be critical to neutralise the inherent tumour-promoting activity of therapy-generated debris.”

Panigrahy and colleagues’ analysis revealed that chemotherapy-killed ovarian cancer cells induce surrounding immune cells called macrophages to release a surge of immune-related chemical compounds – cytokines and lipid mediators – that create optimal conditions in which tumours can survive and grow.

Next, the team showed that a common anti-inflammatory drug called a dual COX-2 inhibitor to block that surge of tumour-friendly cytokines and lipids. 

“The role of these chemotherapy-induced cytokines and lipids is under-appreciated and poorly characterised, and ovarian cancer patients may benefit from suppressing their release,” said Panigrahy.

“Further research is needed but, dual inhibition of the COX-2 pathways is a novel therapeutic modality that may compliment conventional cancer therapies by acting as a surge protector against cell debris-stimulated tumour growth.”

Source: Beth Israel Deaconess Medical Center



Please click on the 'New Comment' link to the left to add a new comment, or alternatively click any 'Add Comment' link next to any existing post to respond. The views expressed here are not those of ecancer. For more information please view our Privacy Policy.

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation